EcoDrugPlus

Dna Topoisomerase 1-Like

Ensembl ID : ENSPNAG00000009507
Gene Symbol: LOC108440338
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase 2-Beta-Like

Ensembl ID : ENSPNAG00000023356
Gene Symbol: LOC108410493
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSPNAG00000007064
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSPNAG00000007424
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSPNAG00000013082
Gene Symbol: EML4
4 Cross references
212 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSPNAG00000018307
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPNAG00000021338
Gene Symbol: F2RL3
3 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSPNAG00000028113
Gene Symbol: FAU
3 Cross references
20 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSPNAG00000015714
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSPNAG00000013506
Gene Symbol: GPR84
3 Cross references
113 Possible Orthologues:

Gtpase Kras

Ensembl ID : ENSPNAG00000028629
Gene Symbol: LOC108428819
3 Cross references
208 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPNAG00000009153
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).